Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 3.

Robert, Caroline; Flaherty, Keith; Nathan, Paul; Hersey, Peter; Garbe, Claus; Milhem, Mohammed; Demidov, Lev; Mohr, Peter; Hassel, Jessica C; Rutkowski, Piotr; Dummer, Reinhard; Utikal, Jochen; Kiecker, Felix; Larkin, James; D'Amelio, Anthony; Mookerjee, Bijoyesh; Schadendorf, Dirk (2019). Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma. European Journal of Cancer, 109:61-69.

Long, Georgina V; Hauschild, Axel; Santinami, Mario; Atkinson, Victoria; MandalĂ , Mario; Chiarion-Sileni, Vanna; Larkin, James; Nyakas, Marta; Dutriaux, Caroline; Haydon, Andrew; Robert, Caroline; Mortier, Laurent; Schachter, Jacob; Schadendorf, Dirk; Lesimple, Thierry; Plummer, Ruth; Ji, Ran; Zhang, Pingkuan; Mookerjee, Bijoyesh; Legos, Jeff; Kefford, Richard; Dummer, Reinhard; Kirkwood, John M (2017). Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. New England Journal of Medicine, 377(19):1813-1823.

Grob, Jean Jacques; Amonkar, Mayur M; Karaszewska, Boguslawa; Schachter, Jacob; Dummer, Reinhard; Mackiewicz, Andrzej; Stroyakovskiy, Daniil; Drucis, Kamil; Grange, Florent; Chiarion-Sileni, Vanna; Rutkowski, Piotr; Lichinitser, Mikhail; Levchenko, Evgeny; Wolter, Pascal; Hauschild, Axel; Long, Georgina V; Nathan, Paul; Ribas, Antoni; Flaherty, Keith; Sun, Peng; Legos, Jeffrey J; McDowell, Diane Opatt; Mookerjee, Bijoyesh; Schadendorf, Dirk; Robert, Caroline (2015). Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncology, 16(13):1389-1398.

This list was generated on Fri May 24 19:41:41 2019 CEST.